{"id":"W4411294413","doi":"10.1002/pbc.31831","title":"Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum","year":2025,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"EMD Serono; Norgine; University of Southampton; Recordati Rare Diseases; Y-mAbs Therapeutics; BeiGene; Eli Lilly and Company; AstraZeneca; Foghorn Therapeutics; Merck KGaA; Gilead Sciences; Royal Marsden NHS Foundation Trust; Amgen; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Medicine; Neuroblastoma; Drug development; Drug; Statement (logic); Pharmacology; Law; Political science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03746947,0.002059064,0.002757668,0.002285842,0.003010069,0.008236032,0.007552154,0.03909357,0.006272523],"category_scores_gemma":[0.02960282,0.00107288,0.004844966,0.002543417,0.002771506,0.006770142,0.008122031,0.03705095,0.006905025],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008727285,"about_ca_system_score_gemma":0.06485858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009013028,"about_ca_topic_score_gemma":0.01558312,"domain_scores_codex":[0.983528,0.003458733,0.002270429,0.001261782,0.006923131,0.002557832],"domain_scores_gemma":[0.9526037,0.008894001,0.003186562,0.0009983713,0.01926518,0.0150522],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005925375,0.0001366,0.0002275913,0.0007170624,0.00002883537,0.0001714358,0.0001147711,0.000273626,0.0004759729,0.00397466,0.9356349,0.05818522],"study_design_scores_gemma":[0.00008802649,0.00008352378,0.0003827735,0.002502239,0.00005093529,0.0002087403,0.0001278157,0.0001757779,0.0002884679,0.004114273,0.9919293,0.0000481441],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.0004636818,0.05053921,0.001887465,0.8819303,0.05548909,0.0004057811,0.0006978944,0.0001671097,0.008419482],"genre_scores_gemma":[0.004086346,0.07723372,0.01245136,0.8542187,0.02816513,0.0008528914,0.002061036,0.0002042236,0.02072649],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.03909357,"threshold_uncertainty_score":0.1981598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05592687186458617,"score_gpt":0.3537812483370361,"score_spread":0.2978543764724499,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}